Congenital myasthenic syndrome (DOK7)

Overview

Congenital myasthenic syndrome (CMS) refers to a group of rare genetic conditions that impair the transmission of signals from nerves to muscles at the neuromuscular junction. This critical junction is where nerve impulses are converted into muscle contractions. In CMS caused by changes in the DOK7 gene, this communication is disrupted, leading to muscle weakness and fatigue [PMID:24855010]. Milder forms of DOK7-associated CMS may present in childhood, while more severe forms can be noticeable at birth. The condition is progressive, meaning symptoms can worsen over time, but the rate and extent of progression are variable. It affects voluntary muscles throughout the body.

Symptoms & clinical features

The symptoms of DOK7 CMS can vary in onset and severity. Often, the earliest signs involve weakness in muscles of the limbs and trunk, which can lead to difficulties with walking, running, and climbing stairs. Some individuals may experience a characteristic waddling gait [PMID:20885175]. Weakness in the neck muscles can cause a 'dropped-head' syndrome, where individuals struggle to hold their head upright. Eye movement muscles are typically unaffected, which helps distinguish DOK7 CMS from some other forms of myasthenic syndromes. Respiratory muscle weakness can also occur, which may lead to breathing difficulties, especially during activity or illness [PMID:24855010]. Symptoms typically worsen with physical activity and improve with rest.

Video: Genetics 101

Affected organs

DOK7 CMS primarily affects the voluntary muscles throughout the body. These include muscles responsible for movement of the limbs, trunk, and neck. The muscles involved in breathing can also be affected, leading to potential respiratory complications. Unlike some other forms of myasthenia, the muscles controlling eye movement are generally spared, meaning double vision or drooping eyelids (ptosis) are less common in DOK7 CMS.

Brain

Central nervous system involvement

Cellular impact

Mechanism at cellular level

Risks & severity

The severity of DOK7 CMS varies significantly, ranging from mild weakness with a relatively good prognosis to severe forms with significant respiratory compromise. The condition is generally progressive, with muscle weakness often worsening over time. While the exact prevalence is not well established, DOK7 CMS is considered a rare condition, representing a significant proportion of CMS cases in some populations [PMID:20885175]. Onset typically occurs in childhood, but symptoms can sometimes appear earlier or later. Respiratory crises, which are episodes of severe breathing difficulty, are a significant risk. These can be triggered by infections, certain medications, or physical exertion and require prompt medical attention. Regular monitoring of respiratory function is an important part of managing the condition.

Genetic causes

Congenital myasthenic syndrome associated with DOK7 is caused by pathogenic variants in the DOK7 gene. This gene provides instructions for making a protein called docking protein 7, which plays a crucial role in the formation and maintenance of the neuromuscular junction. The neuromuscular junction is the specialised point of contact where nerve cells transmit signals to muscle cells, triggering muscle contraction. The DOK7 protein helps organise the necessary components at the neuromuscular junction, ensuring efficient signal transmission. When pathogenic changes occur in the DOK7 gene, the DOK7 protein may be faulty or absent. This disrupts the normal development and function of the neuromuscular junction, leading to impaired communication between nerves and muscles and, consequently, muscle weakness [PMID:20885175].

• DOK7
  docking protein 7
  The DOK7 gene provides instructions for a protein crucial in forming and maintaining connections between nerve cells and muscle cells, known as the neuromuscular junction.

Inheritance pattern

DOK7-related congenital myasthenic syndrome is inherited in an autosomal recessive pattern. This means that an individual must inherit two altered copies of the DOK7 gene - one from each parent - to develop the condition. People who have only one altered copy of the DOK7 gene are called carriers. Carriers typically do not show symptoms of the condition themselves. If both parents are carriers of a pathogenic DOK7 variant, there is a 1 in 4 (25%) chance with each pregnancy that their child will inherit two altered copies and develop the condition. There is a 2 in 4 (50%) chance that their child will be a carrier, and a 1 in 4 (25%) chance that their child will inherit two unaffected copies of the gene and will not be a carrier or have the condition.

Diagnosis & testing

Diagnosing DOK7 CMS typically involves a combination of clinical evaluation, specialised tests, and genetic testing. Doctors may look for characteristic symptoms alongside tests such as electromyography (EMG) or nerve conduction studies, which assess nerve and muscle function. Confirmation of DOK7 CMS is primarily achieved through genetic testing, which identifies pathogenic variants in the DOK7 gene. In the UK, genetic testing for congenital myasthenic syndromes, including DOK7, is available through the NHS Genomic Medicine Service. Referrals for genetic testing are usually made by a neurologist or a clinical geneticist, often following an R-code associated with neuromuscular conditions (e.g., R146 Congenital myasthenic syndromes).

Management & lifestyle

Management of DOK7 CMS focuses on symptom control and preventing complications. While there is currently no cure, specific medications can help improve muscle strength and reduce fatigue for some individuals. These may include certain drugs that enhance neuromuscular transmission. Physiotherapy and occupational therapy can help maintain muscle function, improve mobility, and adapt daily activities. Regular monitoring of respiratory function is essential, and individuals with DOK7 CMS should be aware of factors that can worsen symptoms, such as certain medications or infections. A multidisciplinary clinical team, including neurologists, respiratory specialists, and genetic counsellors, often manages care. The NHS provides comprehensive support for individuals with rare conditions, including access to specialist centres.

UK care pathway

In the UK, individuals suspected of having a congenital myasthenic syndrome, including DOK7 CMS, typically enter the NHS Genomic Medicine Service pathway. This often begins with a referral from a general practitioner or specialist to a neurology clinic. If a genetic cause is suspected, referral to a clinical genetics service or a specialist neuromuscular centre may follow. Genetic testing, guided by NHS R-codes such as R146 for congenital myasthenic syndromes, can confirm the diagnosis. Genetic counsellors play a vital role in providing information about inheritance, risks to family members, and supporting families through the diagnostic process. Ongoing management is typically coordinated by a specialist multidisciplinary team.

Related conditions

Several conditions can present with similar symptoms to DOK7 CMS, primarily muscle weakness and fatigue. These include other types of congenital myasthenic syndromes caused by different genes, which may affect different components of the neuromuscular junction. Myasthenia gravis, an autoimmune condition, is another cause of acquired muscle weakness that can mimic CMS. Careful diagnosis, including genetic testing, is essential to differentiate between these conditions, as their specific management strategies can differ.

Frequently asked questions